

Granules India's 'Breast Health Express' Brings Life-Saving Screenings to Women Police Officers

Hyderabad, 3rd April 2025: As part of its Corporate Social Responsibility (CSR) initiative, Granules India Limited, a leading pharmaceutical company based in Hyderabad in collaboration with AIG Hospitals, successfully conducted a Breast Health Screening and Awareness Camp for women police officials at the Telangana State Police Headquarters. This initiative underscores Granules India's commitment to addressing gaps in women's healthcare, with a particular emphasis on early detection for prevention of breast cancer.

Women police officers dedicate their lives to safeguarding communities, often putting their health on the back burner. With demanding and high stress working hours, they often struggle to prioritize preventive healthcare. Recognizing this, Granules India's 'Breast Health Express' initiative raised awareness about breast health, empowering them with knowledge of regular self-examination and cancer screening services while promoting the importance of early detection. The camp offered breast health screenings and awareness sessions for 100 women police officials.

Since its launch in September 2024, the mobile screening unit has conducted 18 camps, screening over 1,000 women and reaching more than 2,000 individuals through educational sessions. The initiative brings together the collective efforts of Granules India Ltd, AIG Hospitals, Asian Medical Foundation, and UC Breast Foundation. This multi-organizational approach integrates medical expertise, state-of-the-art mobile unit with mammography and ultrasound capabilities and facilities for essential health checks such as haemoglobin and blood pressure, and community outreach to enhance healthcare accessibility for women in underserved communities.

Dr Jitendra IPS, Director General of Police, Telangana State, lauded the initiative, stating, *"One of the biggest challenges with breast cancer is late detection. However, women in demanding professions like law enforcement often prioritize duty over personal health, leading to delayed screenings. Early detection drastically improves treatment success and recovery. I strongly urge every woman above 40 to undergo a breast cancer screening annually or at least every alternate year. This initiative by Granules India and AIG Hospitals is a commendable step in ensuring our women officers receive the preventive healthcare they deserve. By prioritizing early detection, we can safeguard the health and well-being of women across Telangana."*

Dr. Pragnya Chigurupati, Consultant Breast Oncologist at AIG Hospitals and Founder of UC Breast Foundation, highlighted the urgency of breast cancer awareness, stating, *"India, more so Telangana, continues to witness an alarming rise in the number of breast cancer cases. 'Breast Health Express' aims to bring early detection closer to the homes of women via mammogram and ultrasound screening. Through the UC Breast Foundation, we would be able to provide financial assistance to those women who need treatment for breast issues."*

Mrs. Uma Chigurupati, Executive Director of Granules India Ltd, has been a key driving force behind the company's CSR efforts, ensuring that initiatives like Breast Health Express focus on making breast cancer

prevention accessible to all women. Her leadership has been instrumental in shaping Granules India's vision for community health and well-being.

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast-growing Indian pharmaceutical company headquartered in Hyderabad with best-in-class facilities and a commitment to operational excellence, quality, and customer service. Amongst the few pharmaceutical companies in the world to be present across the manufacturing of

the entire pharmaceutical value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs), Granules products are distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US and UK. The Company has 10 manufacturing facilities out of which 8 are located in India and 2 are in the USA and has regulatory approvals from the US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

For more information about Granules India Ltd and its initiatives, please visit www.granulesindia.com